CRIS
Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1
Browse
20 results
Search Results
Now showing 1 - 10 of 20
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, How I Do It: Evaluating Cardiac Implantable Devices and Noncardiac Mimics on Chest Radiographs(Radiological Society of North America (RSNA), 2025-05-01); Jared D. ChristensenThis article provides a comprehensive review of the radiographic appearances of cardiac implantable electronic devices, other cardiac support apparatuses, and similar-appearing noncardiac devices, emphasizing the importance of accurate identification and evaluation for potential complications.6 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Assessing Pulmonary Epithelial Damage in Hantavirus Cardiopulmonary Syndrome: Challenging the Predominant Role of Vascular Endothelium through sRAGE as a Potential Biomarker(2023); ; ; Hantavirus cardiopulmonary syndrome (HCPS) is a severe respiratory illness primarily associated with microvascular endothelial changes, particularly in the lungs. However, the role of the pulmonary epithelium in HCPS pathogenesis remains unclear. This study explores the potential of soluble Receptors for Advanced Glycation End-products (sRAGE) as a biomarker for assessing pulmonary epithelial damage in severe HCPS, challenging the prevailing view that endothelial dysfunction is the sole driver of this syndrome. We conducted a cross-sectional study on critically ill HCPS patients, categorizing them into mild HCPS, severe HCPS, and negative control groups. Plasma sRAGE levels were measured, revealing significant differences between the severe HCPS group and controls. Our findings suggest that sRAGE holds promise as an indicator of pulmonary epithelial injury in HCPS and may aid in tracking disease progression and guiding therapeutic strategies. This study brings clarity on the importance of investigating the pulmonary epithelium’s role in HCPS pathogenesis, offering potential avenues for enhanced diagnostic precision and support in this critical public health concern.1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Scopus© Citations 30 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Successful use of mild therapeutic hypothermia as compassionate treatment for severe refractory hypoxemia in COVID-19(2021)2Scopus© Citations 13 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Pulmonary imaging in coronavirus disease 2019 (COVID-19): a series of 140 Latin American children(2021)10Scopus© Citations 10 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Tool for Estimating the Probability of Having COVID-19 With 1 or More Negative RT-PCR Results(2021)3Scopus© Citations 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Secuestro pulmonar extralobar del lóbulo ácigos: reporte de un caso de ubicación inhabitual(2023); 7 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Síndrome de Mounier-Kuhn: reporte de caso y revisión de la literatura(2022)25 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Respiratory drive, inspiratory effort, and work of breathing: review of definitions and non-invasive monitoring tools for intensive care ventilators during pandemic times(2022)Scopus© Citations 1 12 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes<jats:p>Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines different vaccine technologies and heterologous boosters. From a population-based study performed in November 2021, we randomly selected 120 seropositive individuals, organized into six groups of positive samples (20 subjects each) according to natural infection history and the five most frequent vaccination schemes. We conclude that the booster dose, regardless of vaccine technology or natural infection, and mRNA vaccines significantly improve nAbs response.</jats:p>Scopus© Citations 3 3